TRPC6 and Hyperglycemia: Treatment with STZ at lower dose (50 mg/kg) failed to cause cardiac dysfunction in TRPC6(−/−) mice despite significant increase in blood glucose level equivalent to that in high-dose STZ-treated mice (>400 mg/dl), but significantly potentiated hyperglycemia-induced increase in cardiac MDA concentration in WT hearts (Fig. 3i).